HUTCHMED says SAFFRON Phase III trial of savolitinib — osimertinib combo beats chemo in EGFR — mutant NSCLC after osimertinib progression
HUTCHMED flagged new data for savolitinib with osimertinib at ESMO Congress 2026 in Madrid on Oct. 23-27. Results will be presented in future oral sessions from two positive Phase III studies, including a Presidential Symposium slot. SAFFRON showed the chemo-free regimen improved patient outcomes versus platinum-based chemotherapy in EGFR-mutated NSCLC with MET-driven resistance. SANOVO showed better outcomes versus osimertinib alone in previously untreated EGFR-mutated advanced NSCLC with MET overexpression. Additional posters will update data across fruquintinib and surufatinib programs, extending readouts in colorectal, renal, pancreatic, and neuroendocrine cancers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HUTCHMED (China) Ltd. published the original content used to generate this news brief via (Ref. ID: 202609232000PRIMZONEFULLFEED9832555) on September 24, 2026, and is solely responsible for the information contain
HUTCHMED flagged new data for savolitinib with osimertinib at ESMO Congress 2026 in Madrid on Oct. 23-27. Results will be presented in future oral sessions from two positive Phase III studies, including a Presidential Symposium slot. SAFFRON showed the chemo-free regimen improved patient outcomes versus platinum-based chemotherapy in EGFR-mutated NSCLC with MET-driven resistance.
SANOVO showed better outcomes versus osimertinib alone in previously untreated EGFR-mutated advanced NSCLC with MET overexpression. Additional posters will update data across fruquintinib and surufatinib programs, extending readouts in colorectal, renal, pancreatic, and neuroendocrine cancers. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice.
HUTCHMED (China) Ltd. published the original content used to generate this news brief via (Ref. ID: 202609232000PRIMZONEFULLFEED9832555) on September 24, 2026, and is solely responsible for the information contained therein. (C)